These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 15692065)

  • 1. A novel CDK inhibitor, CYC202 (R-roscovitine), overcomes the defect in p53-dependent apoptosis in B-CLL by down-regulation of genes involved in transcription regulation and survival.
    Alvi AJ; Austen B; Weston VJ; Fegan C; MacCallum D; Gianella-Borradori A; Lane DP; Hubank M; Powell JE; Wei W; Taylor AM; Moss PA; Stankovic T
    Blood; 2005 Jun; 105(11):4484-91. PubMed ID: 15692065
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ataxia telangiectasia mutated-deficient B-cell chronic lymphocytic leukemia occurs in pregerminal center cells and results in defective damage response and unrepaired chromosome damage.
    Stankovic T; Stewart GS; Fegan C; Biggs P; Last J; Byrd PJ; Keenan RD; Moss PA; Taylor AM
    Blood; 2002 Jan; 99(1):300-9. PubMed ID: 11756185
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Microarray analysis reveals that TP53- and ATM-mutant B-CLLs share a defect in activating proapoptotic responses after DNA damage but are distinguished by major differences in activating prosurvival responses.
    Stankovic T; Hubank M; Cronin D; Stewart GS; Fletcher D; Bignell CR; Alvi AJ; Austen B; Weston VJ; Fegan C; Byrd PJ; Moss PA; Taylor AM
    Blood; 2004 Jan; 103(1):291-300. PubMed ID: 12958068
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cyclin-dependent kinase inhibitor Roscovitine induces apoptosis in chronic lymphocytic leukemia cells.
    Hahntow IN; Schneller F; Oelsner M; Weick K; Ringshausen I; Fend F; Peschel C; Decker T
    Leukemia; 2004 Apr; 18(4):747-55. PubMed ID: 14973497
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mdm2 inhibitor Nutlin-3a induces p53-mediated apoptosis by transcription-dependent and transcription-independent mechanisms and may overcome Atm-mediated resistance to fludarabine in chronic lymphocytic leukemia.
    Kojima K; Konopleva M; McQueen T; O'Brien S; Plunkett W; Andreeff M
    Blood; 2006 Aug; 108(3):993-1000. PubMed ID: 16543464
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutations in the ATM gene lead to impaired overall and treatment-free survival that is independent of IGVH mutation status in patients with B-CLL.
    Austen B; Powell JE; Alvi A; Edwards I; Hooper L; Starczynski J; Taylor AM; Fegan C; Moss P; Stankovic T
    Blood; 2005 Nov; 106(9):3175-82. PubMed ID: 16014569
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The potential anticancer agent PK11195 induces apoptosis irrespective of p53 and ATM status in chronic lymphocytic leukemia cells.
    Santidrián AF; Cosialls AM; Coll-Mulet L; Iglesias-Serret D; de Frias M; González-Gironès DM; Campàs C; Domingo A; Pons G; Gil J
    Haematologica; 2007 Dec; 92(12):1631-8. PubMed ID: 18055986
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of NF-κB-mediated signaling by the cyclin-dependent kinase inhibitor CR8 overcomes prosurvival stimuli to induce apoptosis in chronic lymphocytic leukemia cells.
    Cosimo E; McCaig AM; Carter-Brzezinski LJ; Wheadon H; Leach MT; Le Ster K; Berthou C; Durieu E; Oumata N; Galons H; Meijer L; Michie AM
    Clin Cancer Res; 2013 May; 19(9):2393-405. PubMed ID: 23532892
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Seliciclib (CYC202 or R-roscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity via down-regulation of Mcl-1 in multiple myeloma.
    Raje N; Kumar S; Hideshima T; Roccaro A; Ishitsuka K; Yasui H; Shiraishi N; Chauhan D; Munshi NC; Green SR; Anderson KC
    Blood; 2005 Aug; 106(3):1042-7. PubMed ID: 15827128
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Hsp90 inhibitor SNX-7081 synergizes with and restores sensitivity to fludarabine in chronic lymphocytic leukemia cells with lesions in the TP53 pathway: a potential treatment strategy for fludarabine refractory disease.
    Best OG; Che Y; Singh N; Forsyth C; Christopherson RI; Mulligan SP
    Leuk Lymphoma; 2012 Jul; 53(7):1367-75. PubMed ID: 22149137
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hsp90 inhibition has opposing effects on wild-type and mutant p53 and induces p21 expression and cytotoxicity irrespective of p53/ATM status in chronic lymphocytic leukaemia cells.
    Lin K; Rockliffe N; Johnson GG; Sherrington PD; Pettitt AR
    Oncogene; 2008 Apr; 27(17):2445-55. PubMed ID: 17982489
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro activity of cyclin-dependent kinase inhibitor CYC202 (Seliciclib, R-roscovitine) in mantle cell lymphomas.
    Lacrima K; Valentini A; Lambertini C; Taborelli M; Rinaldi A; Zucca E; Catapano C; Cavalli F; Gianella-Borradori A; Maccallum DE; Bertoni F
    Ann Oncol; 2005 Jul; 16(7):1169-76. PubMed ID: 15851403
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Functional analysis of the ATM-p53-p21 pathway in the LRF CLL4 trial: blockade at the level of p21 is associated with short response duration.
    Lin K; Adamson J; Johnson GG; Carter A; Oates M; Wade R; Richards S; Gonzalez D; Matutes E; Dearden C; Oscier DG; Catovsky D; Pettitt AR
    Clin Cancer Res; 2012 Aug; 18(15):4191-200. PubMed ID: 22675167
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Cyclin-dependent kinase inhibitor CYC202 (R-roscovitine) inhibits retinoblastoma protein phosphorylation, causes loss of Cyclin D1, and activates the mitogen-activated protein kinase pathway.
    Whittaker SR; Walton MI; Garrett MD; Workman P
    Cancer Res; 2004 Jan; 64(1):262-72. PubMed ID: 14729633
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Seliciclib (CYC202, R-Roscovitine) induces cell death in multiple myeloma cells by inhibition of RNA polymerase II-dependent transcription and down-regulation of Mcl-1.
    MacCallum DE; Melville J; Frame S; Watt K; Anderson S; Gianella-Borradori A; Lane DP; Green SR
    Cancer Res; 2005 Jun; 65(12):5399-407. PubMed ID: 15958589
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Presence of heterozygous ATM deletion may not be critical in the primary response of chronic lymphocytic leukemia cells to fludarabine.
    Cejkova S; Rocnova L; Potesil D; Smardova J; Novakova V; Chumchalova J; Zezulkova D; Borsky M; Doubek M; Brychtova Y; Pospisilova S; Klabusay M; Mayer J; Trbusek M
    Eur J Haematol; 2009 Feb; 82(2):133-42. PubMed ID: 19018867
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia.
    Chen R; Wierda WG; Chubb S; Hawtin RE; Fox JA; Keating MJ; Gandhi V; Plunkett W
    Blood; 2009 May; 113(19):4637-45. PubMed ID: 19234140
    [TBL] [Abstract][Full Text] [Related]  

  • 18. p53 dysfunction in B-cell chronic lymphocytic leukemia: inactivation of ATM as an alternative to TP53 mutation.
    Pettitt AR; Sherrington PD; Stewart G; Cawley JC; Taylor AM; Stankovic T
    Blood; 2001 Aug; 98(3):814-22. PubMed ID: 11468183
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo.
    Weston VJ; Oldreive CE; Skowronska A; Oscier DG; Pratt G; Dyer MJ; Smith G; Powell JE; Rudzki Z; Kearns P; Moss PA; Taylor AM; Stankovic T
    Blood; 2010 Nov; 116(22):4578-87. PubMed ID: 20739657
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Entinostat combined with Fludarabine synergistically enhances the induction of apoptosis in TP53 mutated CLL cells via the HDAC1/HO-1 pathway.
    Zhou Z; Fang Q; Li P; Ma D; Zhe N; Ren M; Chen B; He Z; Wang J; Zhong Q; Wang J
    Life Sci; 2019 Sep; 232():116583. PubMed ID: 31226417
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.